• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Portfolio management

Armonia-backed Biodue buys Farcoderma

  • Alessia Argentieri
  • Alessia Argentieri
  • 05 August 2020
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Milan-listed cosmetics producer Biodue, a portfolio company of Italian private equity firm Armonia, has wholly acquired food supplements specialist Farcoderma.

Biodue already owned a 43% stake in Farmoderma.

Company CEO Francesco Palladini and shareholder Roberto Nisica will reinvest in Farcoderma and retain a minority stake. Palladini will remain as CEO and will be joined by Biodue CEO Vanni Benedetti, who will become president of Farcoderma.

Farcoderma

  • DEAL:

    Portfolio management

  • LOCATION:

    Torre Pallavicina

  • SECTOR:

    Industrial suppliers

  • FOUNDED:

    2006

  • TURNOVER:

    €15m (2019)

Following the deal, the combined group will employ a staff of 200 people and generate annual revenues of around €60m.

Armonia acquired a stake in Biodue in August 2019, in a deal that gave the company an enterprise value of around €64m, equal to 8x its 2019 EBITDA. The company was listed on the Italian stock exchange at the time.

The acquisition was made via a newco named Aurora Dodici, owned by Armonia and the Rovati family's holding company, Fidim. Subsequently, they launched a public offering on the remaining shares of Biodue and delisted the company in December 2019.

The GP deployed capital from its Armonia Italy Fund, which was originally launched with a €700m target – subsequently reduced to €250m – and held a final close on €280m in July 2018. The vehicle invests equity tickets of €25-75m in Italian SMEs operating in the food, luxury, pharmaceuticals, lifestyle and services sectors.

Biodue sells its products to Italian and international pharmaceutical companies, marketing them under its own brands: Pharcos, Selerbe and Biofta. The company generated EBITDA of €8m from revenues of €44m in 2019.

Company
Established in 2006 and based in Torre Pallavicina, near Bergamo, Farcoderma is a producer of food supplements and cosmetics for face, body and hair as well as medical devices and containers, including bottles, plastic tubes, stick packs and syringes for the pharma and cosmetics industries. The company generates revenues of around €15m.

People
Armonia
– Alessandro Grimaldi (CEO).
Biodue - Vanni Benedetti (CEO).
Farcoderma - Francesco Palladini (CEO).

Advisers
Acquirer
- UHY Bompani (financial due diligence); Gitti & Partners (legal); Gatti Pavesi Bianchi (legal).
Vendor - Studio Legale Conti Damini Codeluppi (legal); Studio Associato Parolari (tax).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Portfolio management
  • Southern Europe
  • Industrials
  • Italy
  • Build-up
  • Buy-and-build

More on Portfolio management

An office building with a cloudy sky in the background
PlusServer owner BC Partners seeks sale via Jefferies as loan maturity looms

GP acquired the German cloud solutions group in 2017 via BC European Capital X

  • Exits
  • 15 August 2023
Runners passing the baton
Volpi raises EUR 250m continuation vehicle for 2016-vintage assets

Volpi Capital Investments Conti will hold Dutch geospatial data company Cyclomedia and UK-based surveillance group Digital Barriers

  • Secondaries
  • 28 June 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest – 17 April 2023

Unquote’s selection of the latest add-ons with Triton's BFC Group, Seven2's Groupe Crystal, Palatine's FourNet and more

  • Expansion
  • 17 April 2023
Boardroom discussions and office openings
MJ Hudson business divisions acquired by Apex Group

Sale follows suspension of listed UK-headquartered asset management service provider’s shares in December 2022

  • Advisory
  • 11 April 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013